Outsourcing

Feliza Mirasol is the science editor for 

Podcasts

Following disruption in the bio/pharmaceutical supply chain as a result of the COVID pandemic, the outsourcing industry has learned to adapt and push forward in a climate that is dynamically different. 

Drug Solutions Podcast: Challenges, Sustainability, and Big Trends in Outsourcing Today

Articles

Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.

Ginkgo Bioworks Acquires AAV Capsid Technology and Forms Partnership for Next-Gen CAR-T Cell Therapies

The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines.

New Expansion for BalanCD CHO Media Platform Portfolio for Bioprocessing 

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As new manufacturing processes and technologies are introduced to meet demand and overcome challenges, understanding also needs to improve to ensure the right balance is achieved.  

Balancing Change and Certainty in Manufacturing 

In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.

Scorpius BioManufacturing Announces New Microbial Capacity and New Interim President

Actylis new 30,000-ft² API manufacturing facility is located in Eugene, Ore.

Actylis Opens 30,000-square-foot API Manufacturing Facility

The trends shaping the growth of the biologics outsourcing industry demand attention.

The Logistics of Outsourcing Biologics

The bio/pharma outsourcing industry continues to be integral in the development and manufacture of medicines. 

Outsourcing Still Vital

Quotient Sciences’ facility expansion is designed to increase support for fully integrated drug development programs.

Quotient Sciences Expands Formulation Development Capabilities at Nottingham Facility

Jeong Jin-hyeok is a lead specialist in drug product at Samsung Biologics.

To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.

Contract Manufacturing Services